Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

RET in breast cancer: functional and therapeutic implications.

Morandi A, Plaza-Menacho I, Isacke CM.

Trends Mol Med. 2011 Mar;17(3):149-57. doi: 10.1016/j.molmed.2010.12.007. Epub 2011 Jan 19. Review.

PMID:
21251878
2.

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM.

Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6.

3.

New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?

Birner P, Bartsch R, Schreiber M, Dubsky P, Kenner L.

Future Oncol. 2014 Feb;10(3):333-6. doi: 10.2217/fon.13.267. No abstract available. Erratum in: Future Oncol. 2014 Mar;10(4):696.

PMID:
24559440
4.

Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

Plaza-Menacho I, Mologni L, McDonald NQ.

Cell Signal. 2014 Aug;26(8):1743-52. doi: 10.1016/j.cellsig.2014.03.032. Epub 2014 Apr 3. Review.

PMID:
24705026
5.

Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.

Morandi A, Isacke CM.

Breast Cancer Res. 2014 Jan 28;16(1):301. doi: 10.1186/bcr3608.

6.

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.

Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM.

Oncogene. 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7.

PMID:
20531297
7.

The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.

Wang C, Mayer JA, Mazumdar A, Brown PH.

Breast Cancer Res Treat. 2012 Jun;133(2):487-500. doi: 10.1007/s10549-011-1775-9. Epub 2011 Sep 24.

8.

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Hatem R, Labiod D, Château-Joubert S, de Plater L, El Botty R, Vacher S, Bonin F, Servely JL, Dieras V, Bièche I, Marangoni E.

Int J Cancer. 2016 May 15;138(10):2510-21. doi: 10.1002/ijc.29974. Epub 2016 Jan 6.

9.

Development of RET kinase inhibitors for targeted cancer therapy.

Mologni L.

Curr Med Chem. 2011;18(2):162-75. Review.

PMID:
21110809
10.

RET inhibition: implications in cancer therapy.

Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA.

Expert Opin Ther Targets. 2013 Apr;17(4):403-19. doi: 10.1517/14728222.2013.758715. Epub 2013 Mar 6. Review.

PMID:
23461584
11.

Targeting RET for thyroid cancer therapy.

Lanzi C, Cassinelli G, Nicolini V, Zunino F.

Biochem Pharmacol. 2009 Feb 1;77(3):297-309. doi: 10.1016/j.bcp.2008.10.033. Epub 2008 Nov 6.

PMID:
19028457
12.

Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.

Nguyen M, Miyakawa S, Kato J, Mori T, Arai T, Armanini M, Gelmon K, Yerushalmi R, Leung S, Gao D, Landes G, Haak-Frendscho M, Elias K, Simmons AD.

Clin Cancer Res. 2015 Dec 15;21(24):5552-62. doi: 10.1158/1078-0432.CCR-15-0468. Epub 2015 Aug 3.

13.

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

Dadu R, Hu MN, Grubbs EG, Gagel RF.

Recent Results Cancer Res. 2015;204:227-49. doi: 10.1007/978-3-319-22542-5_11. Review.

PMID:
26494392
14.

Identification and characterization of RET fusions in advanced colorectal cancer.

Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK.

Oncotarget. 2015 Oct 6;6(30):28929-37. doi: 10.18632/oncotarget.4325.

15.

Current review of small molecule Ret kinase inhibitors.

Zuercher WJ, Turunen BJ, Lackey KE.

Mini Rev Med Chem. 2010 Feb;10(2):138-46. Review.

PMID:
20105131
16.

RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.

Lodish MB, Stratakis CA.

Expert Rev Anticancer Ther. 2008 Apr;8(4):625-32. doi: 10.1586/14737140.8.4.625. Review.

17.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.

Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M.

PLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364. eCollection 2015.

18.

Targeting RET receptor tyrosine kinase activation in cancer.

Phay JE, Shah MH.

Clin Cancer Res. 2010 Dec 15;16(24):5936-41. doi: 10.1158/1078-0432.CCR-09-0786. Epub 2010 Oct 7. Review.

19.

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.

PMID:
23526464
20.

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.

Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJ, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, Jones SD, Jordan AM, Lyons AJ, Nikki March H, McDonald NQ, Maguire LA, Mould DP, Purkiss AG, Small HF, Stowell AI, Thomson GJ, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Eur J Med Chem. 2016 Apr 13;112:20-32. doi: 10.1016/j.ejmech.2016.01.039. Epub 2016 Jan 29.

Supplemental Content

Support Center